Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Tools

Park, H, Uronis, H, Kang, Y, Ng, MCH, Enzinger, P, Lee, KW, Rutella, S ORCID: https://orcid.org/0000-0003-1970-7375, Church, SE, Nordstrom, J, Knutson, K, Erskine, C, Wu, T, Yen, J, Franovic, A, Muth, J, Rosales, M, Vadakekolathu, J ORCID: https://orcid.org/0000-0002-2671-4285, Davidson-Moncada, J, Bang, Y and Catenacci, DV, 2019. Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T). Annals of Oncology, 30 (Supp5), v485. ISSN 0923-7534

Full text not available from this repository.

Official URL: https://doi.org/10.1093/annonc/mdz253.015

Item Type:	Journal article
Publication Title:	Annals of Oncology
Creators:	Park, H., Uronis, H., Kang, Y., Ng, M.C.H., Enzinger, P., Lee, K.W., Rutella, S., Church, S.E., Nordstrom, J., Knutson, K., Erskine, C., Wu, T., Yen, J., Franovic, A., Muth, J., Rosales, M., Vadakekolathu, J., Davidson-Moncada, J., Bang, Y. and Catenacci, D.V.
Publisher:	Elsevier
Date:	October 2019
Volume:	30
Number:	Supp5
ISSN:	0923-7534
Identifiers:	Number Type 10.1093/annonc/mdz253.015 DOI S0923753419594017 Publisher Item Identifier 1280111 Other
Divisions:	Schools > School of Science and Technology
Record created by:	Linda Sullivan
Date Added:	30 Jan 2020 09:32
Last Modified:	04 Feb 2022 16:25
URI:	https://irep.ntu.ac.uk/id/eprint/39124